

Cover Story
																																	ClinicalTrials & Tribulations
By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Technological advances are transforming our understanding of cancer, accelerating the evolution of new treatment approaches. In the past decades, researchers deploying new techniques for analyzing DNA have extended our knowledge of inherited genetic abnormalities that can predispose a person to develop colorectal and other cancers. 
In Brief


Funding Opportunities
Clinical Roundup


Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
 - Cancer centers adapt to life without site visits as NIH changes CCSG review
 - GRAIL to use new study results to seek FDA approval of Galleri MCD test
 - Jonathan Licht named president, chief scientific officer at Van Andel Institute
 - Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS
 
            

















